Legal Opinion

In re Ranbaxy Generic Drug Application Antitrust Litig.

United States Judicial Panel on Multidistrict Litigation

Decided February 11, 2019No. MDL No. 2878Published

1Opinion of the Court

SARAH S. VANCE, Chair

Before the Panel:* Plaintiff in an action pending in the Eastern District of New York (César Castillo ) moves under 28 U.S.C. § 1407 to centralize pretrial proceedings in this litigation in the Eastern District of New York or, alternatively, the District of Massachusetts. This litigation consists of four actions pending in three districts, as listed on Schedule A. The actions involve allegations that defendants engaged in anticompetitive conduct in submitting applications for Abbreviated New Drug Applications to improperly secure the "first-to-file" status concerning the…

2Cases cited1 opinion

  1. In re Skelaxin (Metaxalone) Antitrust LitigationUnited States Judicial Panel on Multidistrict Litigation · 2012

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API